share_log

Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'

Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'

Inovio制药公司股价下跌;美国银行启动“中性”计划
Dow Jones Newswires ·  2021/03/24 02:28

DJ Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'

DJ Inovio制药公司股价下跌;美国银行启动“中性”计划

By Michael Dabaie

迈克尔·达拜(Michael Dabaie)著

Inovio Pharmaceuticals Inc. shares were down 6%, to $9.71, in Tuesday afternoon trading.

在周二下午的交易中,Inovio PharmPharmticals Inc.的股价下跌了6%,至9.71美元。

Bank of America initiated coverage on Inovio with a "Neutral" rating and $13 price objective.

美国银行(Bank Of America)对Inovio的覆盖范围为“中性”,目标价为13美元。

"While we see potential from Inovio's DNA medicines pipeline, we see significant COVID-19 value baked into the stock," Bank of America said.

美国银行表示:“虽然我们从英诺威的基因药物管道中看到了潜力,但我们也看到了新冠肺炎的巨大价值。”

Bank of America said that while much of the Inovio debate has become linked to its Covid-19 vaccine INO-4800, the firm sees Inovio's pipeline of DNA-based medicines for indications that include other infectious diseases, HPV-related precancers, and oncology as bigger value drivers.

美国银行表示,虽然英诺威的大部分争论都与其新冠肺炎疫苗INO-4800型有关,但该公司认为英诺威的dna药物流水线将用于治疗其他传染病、人乳头瘤病毒相关的癌症前病变和肿瘤学等更大的价值驱动因素。

"INO-4800 contributes a significant portion of our [sum-of-the-parts net present value] and volatility around the C-19 vaccine landscape is what keeps us at a Neutral rating," Bank of America said.

“INO-4800贡献了我们的很大一部分[各部分之和净现值]而围绕C-19疫苗前景的波动性使我们保持中性评级。“美国银行说。

"We aren't negative on the clinical profile of INO-4800 vs. competition, but rather, we see the C-19 vaccine market as increasingly saturated, with little room for upside for a later market entrant," the analyst note said.

“我们对INO-4800与竞争对手的临床情况并不持负面看法,相反,我们认为C-19疫苗市场正日益饱和,对于较晚的市场进入者几乎没有上升空间,”这份分析师报告说。

Write to Michael Dabaie at michael.dabaie@wsj.com

写信给Michael Dabaie,电子邮件:michael.dabaie@wsj.com

(END) Dow Jones Newswires

(完)道琼通讯社

March 23, 2021 14:28 ET (18:28 GMT)

2021年3月23日14:28美国东部时间(格林尼治标准时间18:28)

Copyright (c) 2021 Dow Jones & Company, Inc.

版权所有(C)2021年道琼斯公司

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发